• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

CEP-32496

CAS No. 1188910-76-0

CEP-32496 ( —— )

产品货号. M10648 CAS No. 1188910-76-0

CEP-32496 是 BRAF(V600E/WT) 和 c-Raf 的高效抑制剂,Kd 为 14 nM/36 nM 和 39 nM。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥437 有现货
5MG ¥721 有现货
10MG ¥1077 有现货
25MG ¥1968 有现货
50MG ¥3216 有现货
100MG ¥4803 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    CEP-32496
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    CEP-32496 是 BRAF(V600E/WT) 和 c-Raf 的高效抑制剂,Kd 为 14 nM/36 nM 和 39 nM。
  • 产品描述
    CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. Phase 1/2.(In Vitro):Agerafenib (CEP-32496) exhibits high potency against several BRAFV600E-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAFV600E versus those containing wild-type BRAF. Agerafenib exhibits potent binding (BRAFV600E Kd=14 nM) and cellular activity (pMEK IC50=82 nM and A375 proliferation IC50=78 nM), with activity in the proliferation assay. Agerafenib also exhibits a favorable CYP450 inhibition profile, with measured IC50 values greater than 10 μM versus the CYP1A2, CYP2C9, CYP2D6, and CYP3A4 isoforms and an IC50=3.4 μM versus CYP2C19. (In Vivo):Oral administration of Agerafenib (CEP-32496) to Colo-205 tumor xenograft-bearing mice results in significant inhibition of pMEK in tumor cell lysates. For instance, a single 30 mg/kg (po) dose of Agerafenib leads to a 50 and 75% inhibition of normalized pMEK in tumor lysates at the 2 and 6 h postdose time point, respectively (p<0.03), while a 55 mg/kg (po) dose resulted in a 75% to 57% (p<0.03) inhibition of pMEK at 2 through 10 h post administration, with normalization to baseline by 24 h. Agerafenib exhibits an exceptional PK profile in mouse, dog, and cynomolgus monkey. Administration of Agerafenib to beagle dogs (single dose of 1 mg/kg iv and 10 mg/kg po) results in low clearance (CL=5.0 (mL/min)/kg) and excellent bioavailability (%F=100). Similarly, in cynomolgus monkey, the administration of Agerafenib (single dose of 1 mg/kg iv and 10 mg/kg po) leads to high oral exposure due to low clearance (CL=6.7 mL/min/kg) and excellent bioavailability (%F=100).
  • 体外实验
    ——
  • 体内实验
    ——
  • 同义词
    ——
  • 通路
    Tyrosine Kinase
  • 靶点
    Bcr-Abl
  • 受体
    Abl1| c-Kit| RET| PDGFRβ| Lck
  • 研究领域
    Cancer
  • 适应症
    ——

化学信息

  • CAS Number
    1188910-76-0
  • 分子量
    517.46
  • 分子式
    C24H22F3N5O5
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO: 9 mg/mL (17.39 mM)
  • SMILES
    COC1=C(OC)C=C2C(OC3=CC=CC(NC(=O)NC4=NOC(=C4)C(C)(C)C(F)(F)F)=C3)=NC=NC2=C1
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Rowbottom MW, et al. J Med Chem, 2012, 55(3), 1082-1105.
产品手册
关联产品
  • Rasagiline

    雷沙吉兰是单胺氧化酶的不可逆抑制剂,用作早期帕金森病的单一疗法或用作更晚期病例的辅助疗法。

  • GNF-5

    GNF-5 是 GNF-2 的类似物,具有改善的药代动力学特性,是 Bcr-Abl 的选择性非 ATP 竞争性抑制剂,IC50 值为 0.22±0.1 uM(野生型 Abl)。

  • CEP-32496

    CEP-32496 是 BRAF(V600E/WT) 和 c-Raf 的高效抑制剂,Kd 为 14 nM/36 nM 和 39 nM。